Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, multicentre, randomised, double-blind, parallel-group, comparative efficacy and safety study of D961H (20 mg once daily) versus placebo for the prevention of gastric and/or duodenal ulcers associated with daily nonsteroidal anti-inflammatory drug (NSAID) use

Next Previous
X
Search
Trial Profile

A phase III, multicentre, randomised, double-blind, parallel-group, comparative efficacy and safety study of D961H (20 mg once daily) versus placebo for the prevention of gastric and/or duodenal ulcers associated with daily nonsteroidal anti-inflammatory drug (NSAID) use

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced ulcer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 26 Oct 2011 Primary endpoint 'Kaplan-Meier-event-free-survival-rate' has been met according to results presented at the 19th United European Gastroenterology Week.
    • 26 Oct 2011 Results presented at the 19th United European Gastroenterology Week.
    • 10 May 2010 Actual patient number (343) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top